People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...

A study led by two undergraduate students at the University of Galway found that GLP-1 receptor agonists, a type of diabetes ...

The study supports prior research that found the same thing.

A MOTHER has revealed that she lost seven stone after using Mounjaro.  Kellie Willey, a make-up and fashion fan from the UK, ...

A statistically significantly lower risk of dementia or cognitive impairment was observed with GLP-1RAs, though not with SGLT2is or pioglitazone.

Preoperative GLP-1RA use was not significantly associated with an increased risk for postoperative aspiration pneumonia or acute respiratory failure.

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...